Loracarbef versus cefaclor in the treatment of urinary tract infections in women
- PMID: 2069382
- PMCID: PMC245091
- DOI: 10.1128/AAC.35.4.750
Loracarbef versus cefaclor in the treatment of urinary tract infections in women
Abstract
In a double-blind, prospective, randomized study, 108 college women with acute urinary tract infections were treated for 7 days with either loracarbef (LY163892) at 200 mg once daily (n = 53) or cefaclor at 250 mg three times daily (n = 55). The cure rates at 5 to 9 days after treatment in the loracarbef and cefaclor groups were 96 and 90%, respectively. Both loracarbef and cefaclor are safe, well tolerated, and effective in the treatment of urinary tract infections in women.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
